A rapid and simple method for constructing stable mutants of *Acinetobacter baumannii*

Jesús Aranda†, Margarita Poza†, Belén G Pardo‡, Soraya Rumbo†, Carlos Rumbo†, José R Parreira†, Patricia Rodríguez-Velo†, Germán Bou†

**Abstract**

**Background:** *Acinetobacter baumannii* is a multidrug-resistant bacterium responsible for nosocomial infections in hospitals worldwide. Study of mutant phenotypes is fundamental for understanding gene function. The methodologies developed to inactivate *A. baumannii* genes are complicated and time-consuming; sometimes result in unstable mutants, and do not enable construction of double (or more) gene knockout mutant strains of *A. baumannii*.

**Results:** We describe here a rapid and simple method of obtaining *A. baumannii* mutants by gene replacement via double crossover recombination, by use of a PCR product that carries an antibiotic resistance cassette flanked by regions homologous to the target locus. To demonstrate the reproducibility of the approach, we produced mutants of three different chromosomal genes (*omp33*, *oxyR*, and *soxR*) by this method. In addition, we disrupted one of these genes (*omp33*) by integration of a plasmid into the chromosome by single crossover recombination, the most widely used method of obtaining *A. baumannii* mutants. Comparison of the different techniques revealed absolute stability when the gene was replaced by a double recombination event, whereas up to 40% of the population reverted to wild-type when the plasmid was disrupting the target gene after 10 passages in broth without selective pressure. Moreover, we demonstrate that the combination of both gene disruption and gene replacement techniques is an easy and useful procedure for obtaining double gene knockout mutants in *A. baumannii*.

**Conclusions:** This study provides a rapid and simple method of obtaining stable mutants of *A. baumannii* free of foreign plasmidic DNA, which does not require cloning steps, and enables construction of multiple gene knockout mutants.

**Background**

*Acinetobacter baumannii* is a Gram-negative coccobacillus that is increasingly recognized as a major pathogen causing nosocomial infections worldwide, particularly in patients admitted to intensive care units [1,2]. *A. baumannii* can cause pneumonia, wound infections, urinary tract infections, bacteremia and meningitis [3,4]. Its clinical significance, especially in recent years, has increased because of the ability of the bacterium to acquire resistance determinants, making it one of the microorganisms threatening the current antibiotic era [5].

The availability of the genome sequences of several strains of *A. baumannii* opens up new perspectives in the study of this bacterial species [6-9]. The artificial introduction of mutations, by molecular techniques, is a useful way of advancing our understanding of the genetics of *A. baumannii*. The method most commonly used to generate *A. baumannii* mutants involves integration of a plasmid into the chromosome by single crossover recombination. This method requires an internal fragment homologous to the target gene cloned into a suicide vector carrying resistance cassettes [10], which is a major limitation for systematic construction of mutants in post-genomic studies of *A. baumannii*. The possibility that a second crossover event will return the mutant to a wild-type phenotype is another important inconvenience. The gene replacement method is a useful way of overcoming these limitations.

* Correspondence: german.bou@sergas.es
† Contributed equally
‡ Servizo de Microbioloxía-INIBIC, Complexo Hospitalario Universitario A Coruña, As Xubias s/n, 15006 A Coruña, Spain
Full list of author information is available at the end of the article

© 2010 Aranda et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gene replacement typically involves transformation of a non-replicating plasmid containing a deleted or modified gene, followed by low-frequency integration of a plasmid into the chromosome and selection for resolution events to identify gene replacement candidates. In fact, in *A. baumannii*, the plasmids pSSK10, pEX100T, and pJQ200 are valuable tools for constructing mutants by this methodology [11-13]. However, these gene replacement methodologies require several subcloning steps and phenotypic screenings. As a means of circumventing these complicated approaches, we have developed a rapid and simple method of inactivating chromosomal genes that does not require cloning steps. Moreover, the mutants grow directly on agar plates containing appropriate antibiotics and are confirmed by a simple PCR assay.

Integration of a linear piece of foreign DNA requires two recombination events, whereby the original genetic material is replaced by the recombinant DNA [14]. The methodology used in the present study is based on electroporation of a recipient *A. baumannii* strain with a linear PCR fragment carrying an antibiotic resistance cassette flanked by regions homologous to the target locus. This method was used successfully to inactivate three chromosomal loci in *A. baumannii* (omp33, oxyR, and soxR). Moreover, the stability of the mutant, gene expression, and the efficiency of gene disruption and gene replacement methods were compared. Finally, the combination of both techniques was found to be an easy and useful method of obtaining double knockout mutants of *A. baumannii*.

**Results**

**Replacement of the *A. baumannii* omp33 gene**

A PCR product containing a kanamycin resistance cassette flanked by 500 bp of the regions surrounding the *omp33* gene (Figure 1a, Table 1) was introduced into the *A. baumannii* ATCC 17978 strain by electroporation. After selection on kanamycin-containing plates, the *A. baumannii* Δomp33::Km mutant was obtained. The frequency of generation of mutants by gene disruption was approximately $10^{-7}$. The PCR tests with locus-specific primers revealed that 2 of 15 clones obtained had replaced the wild-type gene by the kanamycin cassette (Figure 1b). In addition, allelic replacement in mutant clones was further confirmed by sequencing the PCR products obtained (data not shown).

**Disruption of the *A. baumannii* omp33 gene**

The gene disruption method was also used to inactivate the *omp33* gene. Gene disruption was carried out by cloning a 387-pb internal fragment of the *omp33* gene into the pCR-BluntII-TOPO, to obtain the pTOPO33int plasmid (Figure 2a). After transformation of the recombinant plasmid into the *A. baumannii* ATCC 17978 strain and selection on kanamycin-containing plates, the *A. baumannii* omp33::TOPO mutant was obtained. The frequency of generation of mutants by gene disruption was approximately $10^{-5}$. PCR tests with locus-specific primers revealed that all the clones analyzed (10 of approximately 100) contained fragments of the expected size (Figure 2b). In addition, gene disruption in mutant clones was further confirmed by sequencing the PCR products obtained (data not shown).

**Stable maintenance of plasmid insertion into the chromosome requires drugselection**

Gene knockout stability was tested by culturing both the Δomp33::Km and omp33::TOPO *A. baumannii* mutants under nonselective conditions (in the absence of antibiotics). Cultures of the mutant strains were initially grown in LB and at passages 1, 5, and 10, the cultures were dilution plated to obtain individual colonies, with replicate plateings of 100 colonies for each strain on LB and LB supplemented with kanamycin. The frequency of loss of kanamycin resistance in each passage after growth in non-selective conditions was 1% (first), 9% (fifth), and 37% (tenth) for the gene disrupted *omp33::Km* mutant was stable since no reversions were detected in any passage. As expected, when the same experiment was carried out in the presence of selective pressure, both mutants remained stable (all colonies analyzed were resistant to kanamycin).

**Complementation**

Taking advantage of the fact that the Omp33 protein has been identified in the proteome of *A. baumannii* ATCC 17978 strain by 2-DE and MALDITOF/TOF [15], we observed the absence of the Omp33 protein by 2-DE analysis of the Δomp33::Km mutant (Figure 3a). In order to complement the mutant phenotype, we constructed and tested the expression plasmid pET-RA. The wild-type *omp33* gene without its promoter region was cloned into this expression plasmid. This construction was then introduced into the Δomp33::Km mutant strain by electroporation. The cell surface-associated proteins of the wild-type strain and the Δomp33::Km mutant strain complemented with the pET-RA-OMP33 plasmid were extracted and analyzed by 2DE. The Omp33 protein was detected in the mutant complemented with the Omp33 ORF under the control of the β-lactamase CTX-M14 gene promoter of the pET-RA plasmid (Figure 3a).

**Omp33 detection**

Western blot analysis was performed for further confirmation of the absence of Omp33 in the *A. baumannii*
For this purpose, cell surface-associated proteins of wild-type strain, omp33 mutants, and pET-RA-OMP33-complemented mutants were extracted and subjected to Omp33 Western blot analysis (Figure 3b). The Omp33 protein was not detected in the cell surface-associated proteins of the mutants. As expected, the Omp33 protein was detected in the cell surface-associated proteins of both Δomp33::Km and omp33::TOPO mutants containing the pET-RAOMP33 vector.

Reproducibility of the gene replacement method

To ensure reproducibility of the gene replacement method, we produced the gene replacements of oxyR and soxR (Table 1). The same gene replacement method used these genes.

Table 1 Genes of A. baumannii strain ATCC 17978 inactivated in the present study

| Product Name                      | Gene locationa | Lengthb | Locus tagc | Accession number   |
|-----------------------------------|----------------|---------|------------|--------------------|
| Outer membrane protein (Omp33)    | 3789880 to 3790566 | 228     | A1S_3297   | YP_001086288.1     |
| Transcriptional regulator SoxR    | 1547914 to 1548219 | 101     | A1S_1320   | YP_001084350.1     |
| Transcriptional regulator OxyR    | 1150365 to 1151153 | 262     | A1S_0992   | YP_001084026.1     |

*aA. baumannii ATCC 17978 chromosomal coordinates for each gene.
*bThe length is expressed as number of amino acids.
*cBased on National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov.
used to produce the Δomp33::Km mutant was also used to construct the ΔoxyR::Km and ΔsoxR::Km mutants (Figure 4), with the primers listed in Table 2. The PCR tests with locus-specific primers revealed that 2 of the 7 clones obtained for the oxyR gene, and all clones (3) obtained for the soxR gene had replaced the wild-type gene with the kanamycin resistance cassette (Figure 4). In addition, allelic replacement in mutant clones was further confirmed by sequencing the PCR products obtained (data not shown). Transcriptional analyses demonstrated the lack of both oxyR and soxR gene expression in the ΔoxyR::Km and ΔsoxR::Km mutants, respectively (Figure 5).

**Discussion**

Allelic mutation experiments enable investigation of the functions of many unknown genes identified during the sequencing of entire genomes. A number of methods can be used to inactivate bacterial chromosomal genes. As mentioned above, disruption of the *A. baumannii* chromosome can be achieved by integration of a plasmid into the chromosome by single crossover recombination [10]. For this purpose, an internal fragment that is homologous to the target gene must be cloned into a non-replicating plasmid carrying at least one antibiotic resistance cassette. However, the stability of this type of mutant must be taken into account, because if the gene-disrupted mutant cells are grown in a medium lacking antibiotic pressure, the integrated sequence could be removed, and the disrupted gene could revert to the
original wild-type [16]. We tested this possibility, and found that this is indeed the case, as also found in similar studies with *E. coli* [16]. Therefore, one limitation of the method is that the resulting mutants should always be maintained in an appropriate medium containing selective antibiotics. Another disadvantage of the method is that further manipulations of the mutant strain are restricted, because the same vector cannot be used (because undesired recombination events would be highly likely), thus making it impossible to construct multiple gene knockout mutants.

The gene replacement method has recently been used to generate stable *A. baumannii* mutants [11-13]. This method is based on integration of a plasmid containing the inactivated gene of interest into the bacterial chromosome by single crossover recombination, followed by resolution (or excision) of the integrated DNA by a second recombination event, resulting in replacement of the original wild-type gene by the inactivated gene. The key step in this procedure, in *A. baumannii*, is counter-selection (widely used with Gram-negative bacteria) by the detection of sucrose sensitivity in the presence of the *Bacillus subtilis sacB* gene coding for levansucrase [17]. This method of counter-selection has been found to be useful for several other environmental bacteria [11,12,18]. Plasmids pSSK10, pEX100T, and pQ200 have been successfully used to obtain *A. baumannii* mutants by this method [11-13]. However, most bacteria subjected to homologous recombination, even under negative selection for the *sacB* gene, are wild-type and it is not possible to isolate the desired mutant directly [19-21]. Another disadvantage of this method is that integration of the DNA may not always provide the desired replacement, since foreign DNA with low or no sequence homology would rely on illegitimate recombination events, as previously reported for *Acinetobacter* and other species [14,16]. In addition, all of these gene replacement methodologies are time-consuming, and require several steps involving subcloning into a suicide delivery vector followed by electroporation into *E. coli* and subsequent transfer into *A. baumannii* by electroporation or conjugation. To avoid such situations, we propose a method based on the electroporation of *A. baumannii* electrocompetent cells with linear DNA, a PCR product including an antibiotic resistance cassette flanked by regions homologous to the target locus. However, as expected, we noted an important disadvantage of the replacement method (which requires two
recombination events), with respect to the gene disruption method (which only requires one recombination event), i.e. the low efficiency with regard to obtaining mutants ($10^{-7}$ vs. $10^{-5}$). In addition, we observed more illegitimate recombination events with the new method than with the gene disruption technique, since several colonies acquired the resistance antibiotic cassette (confirmed by PCR), although the wild-type target gene was not replaced (Figures 1, 2, and 4). Nevertheless, the new method is a useful genetic tool for systematic generation of knockouts. Moreover, to our knowledge, there are no previous reports of double knockout mutant strains of \emph{A. baumannii}. However, we demonstrate that the combination of both gene disruption and gene replacement techniques is an easy and useful procedure for obtaining double gene-knockout mutants in \emph{A. baumannii}.

Taking into account the results presented here, it intuitively appears that the gene replacement method would be successful with any strain of \emph{A. baumannii}, including clinical strains, with the only limitation being the use of an appropriate antibiotic resistance marker. Although the kanamycin resistance cassette cannot be used in clinical strains (all the clinical strains of \emph{A. baumannii} taken from our collection were kanamycin resistant: data not shown), use of another antibiotic resistance marker such as rifampicin (for which a low level of resistance has been demonstrated in approximately 50% of multidrug-resistant \emph{A. baumannii} clinical isolates in Spain [22,23]), would be appropriate for generating mutants by gene replacement in these problematic strains.

**Conclusions**

We report mutagenesis of three \emph{A. baumannii} genes by use of a simple and rapid method. The method offers advantages such as no cloning steps, stability even in the absence of selective pressure, and the possibility of constructing multiple gene knockout mutants.
The method may therefore facilitate the understanding of the genetics of \textit{A. baumannii}. Although not tested, it is also possible that this novel method may also work with other pathogenic bacteria, in which genetic manipulation techniques are generally less well established than for \textit{E. coli} and other bacterial species. Finally, the gene disruption method is recommended when only one \textit{A. baumannii} gene must be inactivated, and when it is possible to maintain selective pressure, since it is the fastest and most efficient method of producing \textit{A. baumannii} mutants described so far.

### Methods

#### Bacterial strains, plasmids, and growth conditions

Bacterial strains and plasmids used in this study are listed in Table 3. The \textit{E. coli} and \textit{A. baumannii} strains were grown in Luria Bertani (LB) medium [24]. When necessary, kanamycin (50 μg/ml), rifampicin (50 μg/ml), and zeocin (20 μg/ml for \textit{E. coli} and 200 μg/ml for \textit{A. baumannii}) were added to the growth media. All cultures were incubated at 37°C, 180 rpm. The frequency of generation of mutants was calculated as the number of mutants obtained, divided by the total CFU.

#### Table 2 Oligonucleotides used in the present study

| Oligonucleotide name | Sequence (5’ to 3’) | Application |
|----------------------|---------------------|-------------|
| 33intUP              | CTGGTGACGTTGCTTGACA | Construction of the omp33:TOPO mutant |
| 33intDW              | CGTACCGATGATACCGAAG | Construction of the omp33:TOPO mutant |
| 33extUP              | CCTAAACATACCTTTACAC | Confirmation of the omp33:TOPO mutant |
| 33extDW              | CATGTAAGATGCACCAACTGCC | Confirmation of the omp33:TOPO mutant |
| Kmup                 | CGGAATTCCGACTGTTGGA | Kanamycin amplification |
| Kmdw                 | TTCAGAGAAACTGCTGACAG | Kanamycin amplification |
| 33upFW               | GCTGACGCTGAAGACTGCTGAGT | Construction and confirmation of the Δomp33::Km mutant |
| 33upintRV            | CCCAGCTGCAATTCCGGGGCTTAAATACAGCAGTGG | Construction of the Δomp33::Km mutant |
| 33dwFW               | CGTACCGCTTTACGCTGAGT | Construction and confirmation of the Δomp33::Km mutant |
| 33Fwnest              | GCAATTTTGATTTGCTGACGC | Construction of the Δomp33::Km mutant |
| 33Rwnest              | TGATAGCATTCAAGAGG | Construction of the Δomp33::Km mutant |
| OxyupFW              | AGTAAAGAATTTGAAAGAAAAAATATATA | Construction and confirmation of the ΔoxyR::Km mutant |
| OxyFwnest             | GCAACCTGTAGCAGCGGTT | Construction of the ΔoxyR::Km mutant |
| OxyRwvest            | TCAAGCTAGGCTACTATCC | Construction of the ΔoxyR::Km mutant |
| SoxupFW              | ATGAGAACAAAAAATATATA | Construction and confirmation of the ΔsoxS::Km mutant |
| SoxupintRV          | CCCAGCTGCAATTCCGGGGCTTAAATACAGCAGTGG | Construction of the ΔsoxS::Km mutant |
| SoxdwFW              | CTGACGCTTTACGCTGAGT | Construction and confirmation of the ΔsoxS::Km mutant |
| SoxFwnest             | ATGAGAACAAAAAATATATA | Construction and confirmation of the ΔsoxS::Km mutant |
| SoxRwnest             | TAAAGACATAGACAG | Construction and confirmation of the ΔsoxS::Km mutant |
| ATG33XbaI*            | ATCGTCTAGACCCGACTTTATCTCTTGTTA | Cloning of the omp33 gene |
| STOP33NcoI*          | ATCGCCTAGACCTGACTTTATCTCTTGTTA | Cloning of the omp33 gene |
| SoxRTup              | AGGGAAGATGTTAGGCCAG | RT-PCR for soxR detection |
| SoxRTrv              | CAATCGGAAGAGGACG | RT-PCR for soxR detection |
| OxyRTup              | ATGCGCTGCATACCTCCTACCT | RT-PCR for oxyR detection |
| OxyRTrv              | GCGCTCCTACATACCTTCCAC | RT-PCR for oxyR detection |
| GyrBup               | ATGATGAGTAGCTGCTGACCTAC | RT-PCR for gyrB detection |
| GyrBrv               | CTGAAATACCCCGGCTCAC | RT-PCR for gyrB detection |
| T7                   | AATACCAGACTCTACATAGGCC | Universal primer of the pCR-BluntII-TOPO plasmid |
| SP6                  | ATTTTAGTGACCTACATAG | Universal primer of the pCR-BluntII-TOPO plasmid |
| pETRAFW               | TCTCTCGTGAATATCGTGGATT | Primer of the pET-RA plasmid |
| pETRAFV              | CTGGTCTCATATGCGTGTTGAT | Primer of the pET-RA plasmid |

*Oligonucleotides including the indicated restriction site (underlined).*
DNA manipulations
Genomic and plasmid isolation were performed with a Wizard Genomic DNA Purification Kit (Promega) and Wizard Plus SV Minipreps DNA Purification System (Promega), respectively.Restriction enzymes and DNA-modifying enzymes were purchased from Promega and used according to the manufacturer’s recommendations. Standard PCR amplifications were performed with Bio-Taq DNA polymerase (Bioline). When necessary, high fidelity and blunt-ended PCR products were amplified with Expand High Fidelity (Roche) and Accuzyme (Bioline) DNA polymerases, respectively. All oligonucleotides (Sigma) used in the study are listed in Table 2. PCR products were purified with the High Pure PCR Product Purification Kit (Roche). When high concentrations of purified PCR products were required, a MinElute PCR Purification Kit (Qiagen) was used. All the recombinant plasmids obtained in the study, and the PCR products indicated, were sequenced by the Macrogen sequencing service (Seoul, Korea).

Electroporation
All strains were made electrocompetent as follows. Bacterial overnight cultures were grown in LB broth and subcultured at a dilution of 1:20 in 100 ml of fresh LB medium. Cultures were grown at an OD₆₀₀ of 0.8 and then incubated on ice for 10 min. Cells were pelleted by centrifugation and then washed 3 times with 10% (v/v) glycerol and finally resuspended in 500 μl of 10% (v/v) glycerol. An aliquot of 100 μl of the cell suspension was

![Figure 5](image)

### Figure 5 Transcriptional analysis
RT-PCR analysis of RNA extracted from the wild-type, ΔoxyR::Km, ΔsoxR::Km, ΔoxyR::Km-omp33::TOPO, and ΔsoxR::Km-omp33::TOPO strains showing the lack of oxyR and soxR transcription in the corresponding mutants. The gyrB gene was used as a housekeeping gene. The lengths of cDNAs obtained are indicated.

### Table 3 Bacterial strains and plasmids used in the present study

| Strain or plasmid | Relevant feature(s) | Source or reference |
|-------------------|---------------------|---------------------|
| **Strains**

- Acinetobacter baumannii
  - ATCC 17978
  - omp33::TOPO
  - ΔoxyR::Km
  - ΔsoxR::Km
  - ΔoxyR::Km-omp33::TOPO
  - ΔsoxR::Km-omp33::TOPO

- Escherichia coli
  - TG1

| **Plasmids**

- pCR-BluntII-TOPO
- pTOP33int
- pET-RA
- pET-RA-OMP33

Kan, kanamycin; Zeo, zeocin; Rif, rifampicin.
mixed with the recombinant DNA (up to 20 μl). The mixture was placed in a pre-chilled sterile electroporation cuvette (1 mm electrode gap, Bio-Rad) and immediately pulsed by use of a Bio-Rad Gene Pulser (1.8 kV, 200 W, and 25 μF). The mixture was incubated at 37°C for 1 h with 1 ml of LB broth. Cells were spread on LB agar containing the appropriate antibiotics and incubated at 37°C.

Knockout construction by gene replacement

The upstream and downstream regions (approximately 0.5 kbp each) of the target gene were amplified from genomic DNA of *A. baumannii* ATCC 17978 strain using primer pairs upFW + upintRV and dwintFW + dwRV (Figure 6), respectively. The kanamycin cassette was amplified using primers Kmup and Kmdw (Table 2) and the pCR-BluntII-TOPO vector (Invitrogen) as a template. The upintRV and dwintFW primers (Figure 6) contained, at their 5’ ends, an extension of approximately 20 nucleotides homologous to the Kmup and Kmdw primers, respectively. The three PCR products obtained in the first step were mixed at equimolar concentrations and subjected to a nested overlap-extension PCR with FWnest and RVnest primers (Figure 6) to generate a kanamycin resistance cassette flanked by both the upstream and the downstream gene homologous regions. The nested overlap-extension PCR was carried out with an Expand High Fidelity Taq DNA polymerase (Roche), according to the manufacturer’s recommendations; the conditions used were as follows: 94°C for 15 s, 40°C for 1 min, 72°C for 2 min (10 cycles); 94°C for 15 s, 55°C for 1 min, 72°C for 3 min (20 cycles), and a final extension at 68°C for 10 min. Electroporation of the *A. baumannii* ATCC 17978 strain was performed with approximately 5 μg of the purified PCR product containing the inactivated gene. Cells were then plated on LB agar containing kanamycin for selection of mutants whose wild-type genes were replaced by allelic exchange via double crossover recombination. Gene replacement in candidate clones was verified by PCR with upFW and dwRV primers (Figure 6). Allelic replacement in candidate clones was further confirmed by sequencing the mutant region in the resulting mutants.

Knockout construction by gene disruption

Plasmid insertion in the *omp33* gene (Table 1) was carried out as previously described [10], with slight modifications. Briefly, kanamycin- and zeocin-resistant plasmid pCR-BluntII-TOPO, unable to replicate in *A. baumannii*, was used as a suicide vector. An internal fragment (387 bp) of the *omp33* gene was amplified by PCR with 33intUP and 33intDW primers (Table 2) and genomic DNA from *A. baumannii* ATCC 17978 as a template. The PCR product was cloned into the pCR-BluntII-TOPO vector and electroporated in *E. coli* to yield the pTOPO33int plasmid (Table 3). Recombinant plasmid (0.1 μg) was then introduced in the kanamycin- and zeocin-susceptible *A. baumannii* ATCC 17978 strain by electroporation. Mutants were selected on kanamycin-containing plates. Inactivation of the *omp33* gene by insertion of the plasmid via single crossover recombination was confirmed by sequencing the amplified PCR products with the SP6 + 33extUP and T7 + 33extDW primer pairs (Table 2).

Construction of pET-RA plasmid for gene expression in *A. baumannii*

In order to complement mutant phenotypes, the pET-RA plasmid [Genbank: HM219006] was constructed, and carried a rifampicin resistance cassette, a gene.
coding for a green fluorescent protein (GFP), and the A. baumannii replication origin, which is a plasmid origin of replication (Figure 7). The pET-RA vector was used to express promoterless genes under control of the CTX-M14 β-lactamase gene promoter, previously cloned upstream of the GFP gene (Figure 7). For pET-RA construction, the pMW82 vector [Genbank: EF363313] was amplified by PCR, excluding the coding region of the ampicillin resistance cassette. The rifampicin resistance cassette was then amplified from the pAT-RA vector [Genbank: HM219005] and introduced into the pMW82 vector. The CTXM-14 promoter was cloned into the pMW82 vector BamHI site. The Acinetobacter replication origin was amplified from the pAT-RA vector and cloned into the HindIII site of the pMW82 vector. As a result, the pET-RA vector containing the CTXM-14 promoter was obtained and used for cloning and expression of genes in the XbaI-NcoI restriction sites.

**Complementation of omp33 mutants**

In order to complement the A. baumannii omp33 mutants, the omp33 ORF was amplified with the ATG33XbaI and STOP33NcoI primers (Table 2) from the A. baumannii ATCC 17978 strain genome and cloned into the XbaI-NcoI restriction sites of the pET-RA vector yielding the pET-RA-OMP33 plasmid (Table 3). *Acinetobacter baumannii* omp33 mutants were transformed with the recombinant pETRA-OMP33 plasmid. Transformants were selected on rifampicin- and kanamycin-containing plates and confirmed by PCR with the pETRAFW and pETRARV primers (Table 2).

**Mutant stability assays**

The bacterial cultures were grown in 5 ml of LB broth without kanamycin and incubated at 37°C. Every day, during 10 consecutive days, 100 μl of each culture was diluted in 5 ml of fresh medium and incubated for 24 h. The same experiment was also carried out, for each strain, with medium containing kanamycin. On days 1, 5, and 10, all cultures were diluted 10⁶-fold and dilutions (0.1 ml) were plated on non-selective plates. From these plates, 100 colonies were each transferred to non-selective plates.
selective and selective plates to determine the frequency of revertants, on the basis of the percentage of kanamycin-susceptible colonies.

**RNA methods**

Bacterial cultures were grown overnight in LB broth supplemented with the appropriate antibiotics at 37°C. RNA isolation was performed with the RNeasy Plant Mini Kit (Qiagen). The total RNA extraction was subject to DNaseI (Invitrogen) treatment, following the manufacturer’s instructions. In order to evaluate transcription of the genes of interest, an RT-PCR was performed with the First Strand cDNA Transcriptor Synthesis Kit (Roche) and the gyrB as housekeeping gene. Both the first strand synthesis and the PCR amplification were carried out with the specific primers listed in Table 2. Finally, RT-PCR products were visualized in a 1% agarose gel.

**Protein analysis**

Extraction of *A. baumannii* cell surface-associated proteins and two-dimensional gel electrophoresis (2-DE) were performed as described elsewhere [15]. Proteins were quantified by the Bradford assay, as previously described [25]. Forty μg of protein from each sample was loaded onto a sodium dodecyl sulphate-polyacrylamide gel (12%) in a minigel apparatus (Bio-Rad) and transferred to a Polyvinylidene Fluoride (PVDF) membrane (Roche). To ensure transfer of proteins from the gel, the membrane was stained with Ponceau red. The membrane was then washed, blocked with 5% (wt/vol) blocking agent (non-fat skimmed milk), and incubated with a primary antibody against Omp33 obtained from mouse (INIBIC, A Coruña). Proteins were visualized by incubation with horseradish peroxidase-conjugated secondary antibody, followed by enhanced chemiluminescence ECL Plus (Amersham Pharmacia Biotech) and detected with the LAS3000 chemiluminescence detector (Fujifilm).

**Acknowledgements and Funding**

The present study was supported by grants from SERGAS (PS08/24 and PS07/90) and INCITE 08CSA064916PR from the Xunta de Galicia, by the Spanish Network for Research in Infectious Diseases RD06/0008/0023, and by grants PI081613 and PS09/00687 from the Instituto de Salud Carlos III (Madrid).

**Author details**

1Servicio de Microbiología-INIBIC, Complexo Hospitalario Universitario A Coruña, As Xubias s/n, 15006. A Coruña, Spain. 2Departamento de Xenética. Facultade de Veterinaria. Universidade de Santiago de Compostela. Campus de Lugo. 27002 Lugo, Spain.

**Authors’ contributions**

JA and MP conceived the design of the study, carried out several experimental procedures, and drafted the manuscript. BG and SR participated in the mutant construction and complementation. CR and JR carried out the protein analysis. PR carried out the construction of pET-RA plasmid. GB participated in the design and coordination of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

**Received:** 9 August 2010  **Accepted:** 9 November 2010

**Published:** 9 November 2010

**References**

1. Muñoz-Price LS, Weinstein RA: *Acinetobacter* infection. N Engl J Med 2008, 358(12):1271-1281.

2. Peleg AY, Seifert H, Paterson DL: *Acinetobacter baumannii* emergence of a successful pathogen. Clin Microbiol Rev 2008, 21(3):538-552.

3. Naemi NA, Duim B, Savellkoul PH, Spanjaard L, de Jonge E, Bart A, Vandenbergroucke-Grauls CM, de Jong MD: Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. J Clin Microbiol 2005, 43(9):4862-4864.

4. Fourmier PE, Richet H: The epidemiology and control of *Acinetobacter baumannii* in health care facilities. Clin Infect Dis 2006, 42(5):692-699.

5. Coyne S, Gugan G, Counillon P, Petchon S: Screening and quantification of the expression of antibiotic resistance genes in *Acinetobacter baumannii* with a microarray. Antimicrob Agents Chemother 2010, 54(1):333-340.

6. Smith MG, Gianoulis TA, Pukatzki S, Mekalakos J, Orrston LN, Gerstein M, Snyder M: New insights into *Acinetobacter baumannii* pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. Genes Dev 2007, 21(15):1601-1614.

7. Adams MD, Goglin K, Molyneaux N, Hujer KM, Lavender H, Jamison JJ, MacDonald U, Martin KM, Russo T, Campagnari AA, et al: Comparative genome sequence analysis of multidrug-resistant *Acinetobacter baumannii*. J Bacteriol 2008, 190(24):8053-8064.

8. Vallenet D, Nordmann P, Barbé V, Poiré L, Mangenot S, Bataille E, Dossat C, Gas S, Kreisheimer A, Lenoible P, et al: Comparative analysis of Acinetobacters: three genomes for three lifestyles. PLoS One 2008, 3(3):e1805.

9. Fourmier PE, Vallenet D, Barbé V, Audic S, Ogata H, Poiré L, Richet H, Robert C, Mangenot S, Abergel C, et al: Comparative genomics of multidrug resistance in *Acinetobacter baumannii*. PLoS Genet 2006, 2(11):e7.

10. Heintier C, Poiré L, Lambert T, Nordmann P: Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in *Acinetobacter baumannii*. Antimicrob Agents Chemother 2005, 49(8):3198-3202.

11. Choi AH, Slamti L, Avci FY, Pier GB, Maira-Litran T: The *pgsA*BCD locus of *Acinetobacter baumannii* encodes the production of poly-beta-1-6-N-acetylcglucosamine, which is critical for biofilm formation. J Bacteriol 2009, 191(19):5953-5963.

12. Roca I, Martí S, Espinal P, Martínez P, Gibert I, Vila J: CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in *Acinetobacter baumannii*. Antimicrob Agents Chemother 2009, 53(9):4017-4018.

13. Camarena L, Bruno V, Euskirchen G, Poggio S, Snyder M: Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog 6(4):e1000834.

14. de Vries J, Wackernagel W: Integration of foreign DNA during natural transformation of *Acinetobacter baumannii* sp. by homology-facilitated illegitimate recombination. Proc Natl Acad Sci USA 2002, 99(4):2094-2099.

15. Soares NC, Cabral MP, Pereira Jr, Gayoso C, Barba MJ, Bou G: 2-DE analysis indicates that *Acinetobacter baumannii* displays a robust and versatile metabolism. Proteome Sci 2009, 7:37.

16. Kato C, Ohmiya R, Mizuno T: Integration of foreign DNA during natural transformation of *Acinetobacter baumannii*. Proc Natl Acad Sci USA 2002, 99(4):2094-2099.

17. Soares NC, Cabral MP, Pereira Jr, Gayoso C, Barba MJ, Bou G: 2-DE analysis indicates that *Acinetobacter baumannii* displays a robust and versatile metabolism. Proteome Sci 2009, 7:37.

18. Kato C, Ohmiya R, Mizuno T: Integration of foreign DNA during natural transformation of *Acinetobacter baumannii* sp. by homology-facilitated illegitimate recombination. Proc Natl Acad Sci USA 2002, 99(4):2094-2099.

19. Soares NC, Cabral MP, Pereira Jr, Gayoso C, Barba MJ, Bou G: 2-DE analysis indicates that *Acinetobacter baumannii* displays a robust and versatile metabolism. Proteome Sci 2009, 7:37.

20. Kato C, Ohmiya R, Mizuno T: Integration of foreign DNA during natural transformation of *Acinetobacter baumannii*. Proc Natl Acad Sci USA 2002, 99(4):2094-2099.

21. Soares NC, Cabral MP, Pereira Jr, Gayoso C, Barba MJ, Bou G: 2-DE analysis indicates that *Acinetobacter baumannii* displays a robust and versatile metabolism. Proteome Sci 2009, 7:37.
19. Geng SZ, Jiao XA, Pan ZM, Chen XJ, Zhang XM, Chen X: An improved method to knock out the asd gene of Salmonella enterica serovar Pullorum. J Biomed Biotechnol 2009, 2009:646380.
20. Edwards RA, Keller LH, Schifferli DM: Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression. Gene 1998, 207(2):149-157.
21. Ried JL, Collmer A: An nptI-sacB-sacR cartridge for constructing directed, unmarked mutations in gram-negative bacteria by marker exchange-eviction mutagenesis. Gene 1987, 57(2-3):239-246.
22. Saballs M, Pujol M, Tubau F, Pena C, Montero A, Dominguez MA, Gudiol F, Ariza J: Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006, 58(3):697-700.
23. Fernandez-Cuenca F, Pascual A, Ribera A, Vila J, Bou G, Cisneros JM, Rodriguez-Bano J, Martinez-Martinez L: Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000). Enferm Infecc Microbiol Clin 2004, 22(5):267-271.
24. Miller JH: A short course in bacterial genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1992.
25. Bradford MM: A rapid course in bacterial genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1992.

Cite this article as: Aranda et al: A rapid and simple method for constructing stable mutants of Acinetobacter baumannii. BMC Microbiology 2010 10:279.